November 16, 2018 / 7:31 AM / a month ago

AstraZeneca's pivotal lung cancer trial fails main goal in late stage trial

Nov 16 (Reuters) - AstraZeneca’s combination of two immunotherapy drugs did not meet the main goal in a closely watched late stage study, the company said on Friday.

The trial is testing the drug, Imfinzi, on its own and in combination with tremelimumab. (Reporting by Arathy S Nair in Bengaluru Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below